ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ABL001 works in treating patients with chronic myeloid
leukemia who are on therapy with tyrosine kinase inhibitor. ABL001 may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Giving ABL001 and
tyrosine kinase inhibitor together may work better than tyrosine kinase inhibitor alone in
treating patients with chronic myeloid leukemia.